Shardul Amarchand Mangaldas & Co Pilots ₹3,093 Crore On-Market Sale in Cohance Lifesciences

New Delhi – In a significant capital markets transaction underscoring the dynamic activity within India's pharmaceutical and life sciences sector, Shardul Amarchand Mangaldas & Co (SAM) has successfully acted as the sole legal advisor to Jusmiral Holdings Limited. The deal involved an on-market sale of an 8.93% shareholding in Cohance Lifesciences Limited, a prominent player in the Active Pharmaceutical Ingredient (API) and contract development and manufacturing space. The transaction, valued at a substantial ₹3,093 crore (approximately USD 370 million), marks a key liquidity event and showcases the continued confidence of investors in the sector.

The high-stakes transaction was navigated by a multi-disciplinary team from SAM, led by distinguished Partner Ambarish. The core team providing transactional support included Krishaal Morjaria (Principal Associate) and Varun Natarajan (Senior Associate). Critical advice on the nuanced aspects of securities law was provided by Kanwardeep Singh Kapany (Counsel), while Partner Ameya Gokhale and Principal Associate Kriti Kalyani also contributed with crucial inputs.

Transaction Background and Strategic Context

This on-market sale represents a pivotal chapter in a complex corporate journey that SAM has been intricately involved with. The firm's role extends back to the foundational transactions that created the entity now known as Cohance Lifesciences. As noted in the firm's history with the client, "SAM has earlier advised Advent in its control acquisition of Suven Pharmaceuticals Limited by way of a share purchase and mandatory open offer."

That landmark deal saw private equity giant Advent International acquire a controlling stake in Suven Pharmaceuticals. Following this, SAM also advised on the strategic merger of Cohance, another Advent-controlled entity, into Suven. This complex merger and restructuring culminated in the rebranding of the merged entity as Cohance Lifesciences, creating a scaled-up, end-to-end Contract Development and Manufacturing Organisation (CDMO) and API powerhouse.

The recent ₹3,093 crore stake sale by Jusmiral Holdings (an Advent-affiliated entity) can be seen as a strategic partial exit, allowing the private equity sponsor to crystallise returns on its investment while still retaining a significant interest in the company's future growth. This is a classic private equity lifecycle event, moving from acquisition and value creation through merger and consolidation, to eventual monetization.

Legal Intricacies of an On-Market Block Deal

Executing a large on-market share sale of this magnitude requires meticulous legal planning and a deep understanding of Indian capital markets regulations. While seemingly straightforward compared to a negotiated share purchase agreement, such transactions present their own unique set of legal challenges that the advising firm must navigate.

1. Regulatory Compliance: The primary concern is strict adherence to the regulations set forth by the Securities and Exchange Board of India (SEBI). This includes compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, ensuring that the timing of the sale does not coincide with the possession of any unpublished price-sensitive information (UPSI). The legal team, led by securities law counsel like Kanwardeep Singh Kapany, would have been responsible for vetting the transaction timeline against corporate blackout periods and ensuring all disclosures are properly made.

2. Disclosure Obligations: Large stake sales trigger specific disclosure requirements under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The seller, Jusmiral Holdings, would be obligated to promptly inform the stock exchanges and the target company, Cohance Lifesciences, about the change in its shareholding. The legal advisors are instrumental in drafting and filing these disclosures accurately and within the stipulated timelines to avoid regulatory scrutiny.

3. Execution and Trade Settlement: On-market sales of this size are typically executed through the "block deal window" of the stock exchanges. This mechanism allows for a large quantity of shares to be traded at a single price between two parties, minimizing price impact on the open market. The legal team's role involves coordinating with investment bankers, brokers, and other intermediaries to ensure the trade is executed smoothly and that settlement occurs without any hitches, conforming to the T+1 settlement cycle.

4. Market Impact and Strategy: The legal strategy must also consider the potential market reaction. Advising on the structure and timing of the sale helps the client manage market perception and ensure an orderly transaction that does not cause undue volatility in the stock price.

The Broader Impact on the Legal and Pharmaceutical Sectors

The successful execution of this deal by the Ambarish-led team at Shardul Amarchand Mangaldas highlights the firm's premier position in handling high-value, complex capital markets and M&A transactions. For legal professionals, it serves as a case study in the lifecycle management of a major private equity investment, from the initial control acquisition and complex merger to the eventual strategic stake sale.

Furthermore, the transaction reinforces the bullish outlook for India's pharmaceutical and life sciences industry. The sector continues to attract significant private equity and strategic investment, driven by its strong manufacturing capabilities, R&D potential, and global demand. This sustained deal flow translates into a robust pipeline of work for corporate law firms specializing in M&A, private equity, and capital markets, making it one of the most dynamic and competitive practice areas in the Indian legal landscape. As global supply chains continue to de-risk and diversify, Indian CDMOs and API manufacturers like Cohance Lifesciences are poised for continued growth, promising further M&A and capital market activities in the foreseeable future.